RECEIVED CENTRAL FAX CENTER

MAR 0 4 2005

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paparwork Reduction Act of 1995, to persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 09/937,045 Filing Date TRANSMITTAL September 20, 2001 FORM First Named Inventor Thierry Gallet, et al Art Unit 1624 Examiner Name Coleman, Brenda Libby (to be used for all correspondence after Initial Filing) Attorney Docket Number 6 pas. SYL 531 US PCT Total Number of Pages In This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC ~ Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application
Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify **Terminal Dischaimer** Extension of Time Request below): Request for Refund 1. Amendment Pursuant to 37 C.F.R. Express Abandonment Request § 1.121 And Reply Pursuant to 37 C.F.R. § 1.116 (5 pgs.) CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Cartifled Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature laram Printed name Balaram Gupta Date Reg. No. March 04, 2005 40,009 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 Total No. of Pages Transmitted: _ 6 pgş Signature Date Typed or printed name Maribel Mendez March 04, 2005

This correction of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED CENTRAL FAX CENTER

NO. 2965 P. 2/6

MAR 0 4 2005

PATENT

Docket No.: SYL 531 US PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Thierry Gallet et al.

Examiner:

Coleman, Brenda Libby

Art Unit:

1624

Serial No.: 09/937,045

Filed:

September 20, 2001

TELEFAX CERTIFICATE

Title:

Derivatives of 1,4-Diazabicyclo[3,2,2]-

Nonane-4-Carboxylates and Carboxamides, Their Preparation and Their Therapeutic

Application

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, at (703) 872-9306 on

Mail Stop: AF

Commissioner for Patents

P.O. Box 1450

Arlington, VA 22313-1450

AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY AFTER FINAL PURSUANT TO 37 C.F.R. § 1.116

Sir:

This is a Rule 116 Amendment in the above-identified patent application in response to the Office Action, paper no. 20050106, dated, January 11, 2005, having a response due by April 11, 2005. It is respectfully requested that the following amendments and remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 4.

SYL 531 US PCT